US2023118205A1PendingUtilityA1
Novel compounds (immunorhelins)
Assignee: ISR IMMUNE SYSTEM REGULATION HOLDING AB PUBLPriority: Jan 20, 2017Filed: Aug 16, 2022Published: Apr 20, 2023
Est. expiryJan 20, 2037(~10.5 yrs left)· nominal 20-yr term from priority
A61P 35/02C07K 7/23A61P 31/12A61K 38/00A61P 35/00A61P 37/04A61P 5/02
64
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides immune stimulating peptides (immunorhelins) capable of stimulating GnRH receptors when dosed to human patients or cells. These immunorhelins have utility in treating viral diseases and cancer.
Claims
exact text as granted — not AI-modified1 . A compound of formula (I)
or a pharmaceutically acceptable salt thereof, and wherein
wherein R 5 =Me, Et, CH 2 CF 3 , iPr, nPr, nBu, iBu, sBu, tBu, cyclopropyl CH 2 CONH 2 or NHCONH 2
and with the proviso that the invention does not include the following compounds:
Pro-
viso
R1
R2
R3
R4
R5
P1
CH 2 CONH 2
P2
CH 2 CONH 2
P3
CH 2 CONH 2
P4
CH 2 CONH 2
P5
CH 2 CONH 2
P6
CH 2 CONH 2
P7
Et
P8
Et
P9
CH 2 CONH 2
P10
CH 2 CONH 2
P11
CH 2 CONH 2
P12
Et
P13
Et
P14
Et
P15
NHCONH 2
P16
NHCONH 2
P17
Et
P18
NHCONH 2
P19
Et
P20
NHCONH 2
P21
Et
2 . A compound according to claim 1 , wherein at least one of R 1 , R 3 and R 4 are selected from type II according to the list below, and those of R 1 , R 3 and R 4 which are not selected from type II are selected from Type I according to the list below:
Group
Type I
Type II
R 1
R 3
R 4
3 . A compound according to claim 2 , wherein at least two or three of R 1 , R 3 and R 4 are selected from type II according to the list below:
Group
Type I
Type II
R 1
R 3
R 4
4 . A compound according to claim 2 , wherein one of R 1 , R 3 and R 4 is selected from Type I according to the list below and two of R 1 , R 3 and R 4 are selected from type II according to the list below:
Group
Type I
Type II
R 1
R 3
R 4
5 . A compound according to any of claims 1 to 4 , wherein R 5 =Et or CH 2 CONH 2 .
6 . A compound according to any of claims 1 to 4 wherein R 5 =Me, iPr, nPr, nBu, iBu, sBu or tBu.
7 . A compound according to any one of claims 1 to 6 , wherein the compound of formula (I) is selected from:
Com-
pound
no.
R1
R2
R3
R4
R5
1
CH 2 CONH 2
2
CH 2 CONH 2
3
CH 2 CONH 2
4
CH 2 CONH 2
5
CH 2 CONH 2
6
Et
7
CH 2 CONH 2
8
Et
9
Et
10
Et
11
Et
12
Et
13
Et
14
CH 2 CONH 2
15
Et
16
CH 2 CONH 2
17
Et
18
Et
19
Et
20
Et
21
Et
22
Et
23
CH 2 CONH 2
24
CH 2 CONH 2
25
CH 2 CONH 2
26
Et
27
CH 2 CONH 2
28
CH 2 CONH 2
29
Et
30
CH 2 CONH 2
31
Et
32
Et
33
CH 2 CONH 2
34
Et
35
Et
36
Et
37
CH 2 CONH 2
38
CH 2 CONH 2
39
CH 2 CONH 2
40
CH 2 CONH 2
41
CH 2 CONH 2
42
Et
43
CH 2 CONH 2
44
Et
45
Et
46
CH 2 CONH 2
47
Et
48
Et
49
Et
50
Et
51
CH 2 CONH 2
52
CH 2 CONH 2
53
CH 2 CONH 2
54
CH 2 CONH 2
55
CH 2 CONH 2
56
Et
57
CH 2 CONH 2
58
CH 2 CONH 2
59
Et
60
Et
61
Et
62
Et
63
Et
64
CH 2 CONH 2
65
CH 2 CONH 2
66
CH 2 CONH 2
67
Et
68
CH 2 CONH 2
8 . A pharmaceutical composition comprising a compound according to any one of claims 1 to 7 and one or more pharmaceutically acceptable excipients.
9 . A compound according to any one of claims 1 to 7 for use in medicine.
10 . A compound according to any one of claims 1 to 7 for use in the treatment of viral infections or cancer.
11 . A compound selected from P1-P21 as defined in claim 1 for use in the treatment of viral infections or cancer.
12 . A method for treating or preventing a disease caused by a viral infection comprising administering to a human or animal subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 7 .
13 . A method for treating or preventing a disease caused by a viral infection comprising administering to a human or animal subject in need thereof a therapeutically effective amount of a compound selected from P1-P21 as defined in claim 1 .Join the waitlist — get patent alerts
Track US2023118205A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.